Author:
Czarnecka Anna M.,Fiedorowicz Michał,Bartnik Ewa
Publisher
Springer International Publishing
Reference176 articles.
1. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
2. Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: past, present, and future. Cancers (Basel). 2019;11(8):1197.
3. Cheng L, et al. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38.
4. Hauschild A, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.
5. Rutkowski P, et al. The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial. Contemp Oncol (Pozn). 2015;19(4):280–3.